SLA Pharma AG & KD Pharma Group COVID-19 Clinical Trial Approved

BIOGGIO, SWITZERLAND – April 14, 2020 – The KD Pharma Group (“KD Pharma”) and its partner, SLA Pharma AG (“SLA”), announced that its new drug candidate EPAspireTM is shortly entering clinical trials as a promising candidate to treat…
Feature image - scan of a chronic anal fissure

Meeting with the FDA in October 2019 for ALFA™

SLA Pharma AG are meeting with the FDA in October 2019 to discuss a new drug application for our late stage development ALFA™ for the treatment of familial adenomatous polyposis (FAP). ALFA™ is currently undergoing clinical studies in…
Feature image - scan of a chronic anal fissure

SLA Pharma AG at BIO-Europe 2019

SLA Pharma AG are attending the annual Bio-Europe conference in Hamburg, Germany from November 11th-13th 2019. The BIO-Europe conference is a great opportunity to meet and connect with hundreds of pharmaceutical companies, one-to-one. SLA…
FAP feature image

Alfa – Pharmacist information

Indicated for the treatment of familial adenomatous polyposis & ulcerative colitis.
Feature image - scan of a chronic anal fissure

Anotop – Pharmacist information

Indicated for the treatment of chronic anal fissures.
pilonidal disease feature image

Ortem – Pharmacist information

Indicated for the treatment of pilonidal sinus disease.
Feature image - scan of a chronic anal fissure

Anotop clinical trials

Indicated for the treatment of chronic anal fissures.
FAP feature image

Alfa clinical trials

Indicated for the treatment of familial adenomatous polyposis & ulcerative colitis.
pilonidal disease feature image

Ortem clinical trials

Indicated for the treatment of pilonidal sinus disease.
Feature image - scan of a chronic anal fissure

Anal Fissure